Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells.
Annika NeldeHeiko SchusterJonas S HeitmannJens BauerYacine MaringerMelissa ZwickJens-Peter VolkmerJames Y ChenAnna M Paczulla StangerAriane LehmannBismark AppiahMelanie MärklinElke Rücker-BraunHelmut R SalihMalte RoerdenSarah M SchroederMax-Felix HäringAndreas SchlosserJohannes ScheteligMarc SchmitzMelanie BörriesNatalie StickelClaudia LengerkeRavindra MajetiIrving L WeissmanHans-Georg RammenseeJuliane Sarah WalzPublished in: Blood cancer discovery (2023)
The elimination of therapy-resistant leukemia stem and progenitor cells (LSC) remains a major challenge in the treatment of AML. This study identifies and functionally validates LSC-associated HLA class I and HLA class II-presented antigens, paving the way to the development of LSC-directed T cell-based immunotherapeutic approaches for patients with AML. See related commentary by Ritz, p. 437 .